Alliance Pharma PLC Hardman Research: Potential of Diclectin
25 January 2017 - 6:15PM
RNS Non-Regulatory
TIDMAPH
Alliance Pharma PLC
25 January 2017
Hardman Research: Potential of Diclectin
Potential of Diclectin: Alliance Pharma's buy-and-build strategy
to evolve into a profitable, cash generative, specialty pharma
business is clearly bearing fruit. Acquisition of the dermatology
and woundcare products from Sinclair Pharma was transformational,
doubling the size of the company and providing a more
internationally-oriented business. The enlarged group is also a
more attractive and credible partner for attracting in-licensing
and M&A opportunities. 2017 looks set to be an exciting year
for the group. Not only is there solid growth potential in the
re-focused group, but approval of Diclectin in the UK also offers
significant growth potential.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/25.01.17-potential-of-diclectin.pdf
To contact us: Contact: Dr Martin Hall mh@hardmanandco.com
Hardman & Co Dr Dorothea Hill dmh@hardmanandco.com
11/12 Tokenhouse Dr Gregoire Pave gp@hardmanandco.com
Yard Telephone: +44 20 7929 3399
London Follow us on Twitter @HardmanandCo
EC2R 7AS
www.hardmanandco.com
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEANFLAEFXEFF
(END) Dow Jones Newswires
January 25, 2017 02:15 ET (07:15 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Sep 2023 to Sep 2024